近日,山东新华制药的布洛芬混悬滴剂获批上市并视同过评,该产品是公司首个滴剂产品,具有积极意义。布洛芬是抗炎药和抗风湿药大品种,2024年在中国三大终端六大市场的销售额超过40亿元。今年以来,新华制药已累计拿下了5个新品。图1:山东新华制药最新获批的产品来源:米内网中国申报进度(MED)数据库图2:2024年抗炎药和抗风湿药TOP5品种来源:米内网格局数据库2024年在中国三大终端六大市场(统计范围...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.